Difference between revisions of "ALK inhibitors"
Jump to navigation
Jump to search
| Line 2: | Line 2: | ||
*Alectinib.<ref name=pmid30790150>{{Cite journal | last1 = Honda | first1 = K. | last2 = Kadowaki | first2 = S. | last3 = Kato | first3 = K. | last4 = Hanai | first4 = N. | last5 = Hasegawa | first5 = Y. | last6 = Yatabe | first6 = Y. | last7 = Muro | first7 = K. | title = Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report. | journal = Invest New Drugs | volume = | issue = | pages = | month = Feb | year = 2019 | doi = 10.1007/s10637-019-00742-2 | PMID = 30790150 }}</ref><ref name=pmid29685646>{{Cite journal | last1 = Pal | first1 = SK. | last2 = Bergerot | first2 = P. | last3 = Dizman | first3 = N. | last4 = Bergerot | first4 = C. | last5 = Adashek | first5 = J. | last6 = Madison | first6 = R. | last7 = Chung | first7 = JH. | last8 = Ali | first8 = SM. | last9 = Jones | first9 = JO. | title = Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma. | journal = Eur Urol | volume = 74 | issue = 1 | pages = 124-128 | month = 07 | year = 2018 | doi = 10.1016/j.eururo.2018.03.032 | PMID = 29685646 }}</ref> | *Alectinib.<ref name=pmid30790150>{{Cite journal | last1 = Honda | first1 = K. | last2 = Kadowaki | first2 = S. | last3 = Kato | first3 = K. | last4 = Hanai | first4 = N. | last5 = Hasegawa | first5 = Y. | last6 = Yatabe | first6 = Y. | last7 = Muro | first7 = K. | title = Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report. | journal = Invest New Drugs | volume = | issue = | pages = | month = Feb | year = 2019 | doi = 10.1007/s10637-019-00742-2 | PMID = 30790150 }}</ref><ref name=pmid29685646>{{Cite journal | last1 = Pal | first1 = SK. | last2 = Bergerot | first2 = P. | last3 = Dizman | first3 = N. | last4 = Bergerot | first4 = C. | last5 = Adashek | first5 = J. | last6 = Madison | first6 = R. | last7 = Chung | first7 = JH. | last8 = Ali | first8 = SM. | last9 = Jones | first9 = JO. | title = Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma. | journal = Eur Urol | volume = 74 | issue = 1 | pages = 124-128 | month = 07 | year = 2018 | doi = 10.1016/j.eururo.2018.03.032 | PMID = 29685646 }}</ref> | ||
*Crizotinib. | |||
*Ceritinib. | |||
*Brigatinib. | |||
*Lorlatinib. | |||
==See also== | ==See also== | ||
Revision as of 23:57, 17 March 2019
ALK inhibitors are a group of drugs that act on tumours with ALK rearrangements.
See also
References
- ↑ Honda, K.; Kadowaki, S.; Kato, K.; Hanai, N.; Hasegawa, Y.; Yatabe, Y.; Muro, K. (Feb 2019). "Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report.". Invest New Drugs. doi:10.1007/s10637-019-00742-2. PMID 30790150.
- ↑ Pal, SK.; Bergerot, P.; Dizman, N.; Bergerot, C.; Adashek, J.; Madison, R.; Chung, JH.; Ali, SM. et al. (07 2018). "Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma.". Eur Urol 74 (1): 124-128. doi:10.1016/j.eururo.2018.03.032. PMID 29685646.